Stockscreener 앱 받기
253.20
0.48%
1.22
시간 외 거래:
253.20
전일 마감가:
$251.98
열려 있는:
$254.74
하루 거래량:
565.06K
Relative Volume:
1.62
시가총액:
$27.63B
수익:
$3.81B
순이익/손실:
$-644.79M
주가수익비율:
-40.58
EPS:
-6.24
순현금흐름:
$-669.77M
1주 성능:
-4.48%
1개월 성능:
-2.05%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$252.54
$257.88
1주일 범위
$250.49
$270.60
52주 변동 폭
$172.67
$287.88
Beigene Ltd Adr Stock (ONC) Company Profile
명칭
Beigene Ltd Adr
전화
13459494123
주소
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
ONC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ONC
Beigene Ltd Adr
|
253.20 | 27.63B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
511.74 | 130.95B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
661.00 | 72.29B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
290.70 | 38.57B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ARGX
Argen X Se Adr
|
607.95 | 37.51B | 2.19B | 833.04M | -1.28B | 12.71 |
Beigene Ltd Adr Stock (ONC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-03 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-12-03 | 재개 | Morgan Stanley | Overweight |
| 2024-09-18 | 개시 | JMP Securities | Mkt Outperform |
| 2024-02-06 | 재개 | JP Morgan | Overweight |
| 2023-09-12 | 개시 | Macquarie | Outperform |
| 2023-08-17 | 개시 | Jefferies | Buy |
| 2023-07-17 | 개시 | Citigroup | Buy |
| 2023-06-30 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | 개시 | Daiwa Securities | Buy |
| 2022-10-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-10-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | 재개 | JP Morgan | Overweight |
| 2022-03-17 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | 개시 | Deutsche Bank | Buy |
| 2021-10-12 | 개시 | Bernstein | Outperform |
| 2021-10-06 | 업그레이드 | CLSA | Underperform → Buy |
| 2021-03-08 | 개시 | China Renaissance | Buy |
| 2021-03-01 | 다운그레이드 | CLSA | Outperform → Underperform |
| 2020-11-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-11-06 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
모두보기
Beigene Ltd Adr 주식(ONC)의 최신 뉴스
Beigene director Wang Xiaodong sells $10.9 million in shares By Investing.com - Investing.com South Africa
Beigene director Wang Xiaodong sells $10.9 million in shares - Investing.com India
Beigene’s Wu Xiaobin anticipates $1.06 million from RMB shares sale - Investing.com
Bernstein raises BeiGene stock price target to $259 - Investing.com
BeiGene CEO John Oyler sells $10 million in shares - Investing.com India
Beigene CEO John Oyler sells $10.39 million in shares By Investing.com - Investing.com South Africa
BeiGene Stock: Top Executives Sell Shares Near Record High - Sharewise
Beigene CEO John Oyler sells shares worth $14.6 million By Investing.com - Investing.com South Africa
Beigene CEO John Oyler sells shares worth $14.6 million - Investing.com
Beigene CEO John Oyler sells $10.39 million in shares - Investing.com
BeiGene Ltd. Sponsored ADR to Host Earnings Call - ACCESS Newswire
Beigene’s president Wu Xiaobin sells $13.6 million in shares - Investing.com
Beigene chair Wang Xiaodong sells shares worth over $2 million - Investing.com India
Beigene president sells economic interest in RMB shares for $1.16 million - Investing.com India
China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer - Benzinga
BOCOMI: BEIGENE (06160.HK) Guides to Positive 2025 Operating Profit; Rating Kept at Buy - AASTOCKS.com
JPMorgan maintains BeiGene stock Overweight rating, $311 target - Investing.com India
Beigene SVP sells $331,375 in American depositary shares By Investing.com - Investing.com South Africa
Beigene SVP sells $331,375 in American depositary shares - Investing.com India
JPMorgan maintains BeiGene stock Overweight rating, $311 target By Investing.com - Investing.com South Africa
BofA lifts BeiGene stock rating, raises target to $320 - Investing.com India
BofA lifts BeiGene stock rating, raises target to $320 By Investing.com - Investing.com South Africa
Beigene directors Julian and Felix Baker sell $190m in shares - Investing.com India
BeiGene gets FDA Orphan Drug Designation for sonrotocla - Investing.com
Guggenheim lifts BeiGene stock target to $348, maintains Buy rating - Investing.com India
Citizens JMP lifts BeiGene stock target to $348 on strong sales By Investing.com - Investing.com South Africa
Citizens JMP lifts BeiGene stock target to $348 on strong sales - Investing.com India
AASTOCKS Financial NewsBeiGene, Ltd. (ONC) - AASTOCKS.com
UBS Lifts BEIGENE (06160.HK) TP to $330, Rating Buy - AASTOCKS.com
BeiGene stock price target raised to $334 at TD Cowen By Investing.com - Investing.com South Africa
BeiGene stock price target raised to $334 at TD Cowen - Investing.com
BeiGene stock target raised to $308 on strong FY results - Investing.com India
BeiGene stock target raised to $308 on strong FY results By Investing.com - Investing.com South Africa
BeiGene beats Q4 expectations, sees strong 2025 revenue growth - Investing.com
BeiGene beats Q4 expectations, sees strong 2025 revenue growth By Investing.com - Investing.com South Africa
Beigene SVP sells shares worth $310,169 By Investing.com - Investing.com South Africa
Beigene SVP sells shares worth $310,169 - Investing.com India
Beigene's global head of R&D sells $1.29m in shares - Investing.com
Beigene, Ltd. (NASDAQ:ONC) COO Xiaobin Wu Sells 21,267 Shares - MarketBeat
BeiGene stock soars to 52-week high of $258.66 amid robust growth - Investing.com India
BeiGene stock soars to 52-week high of $258.66 amid robust growth By Investing.com - Investing.com South Africa
BeiGene’s president sells $12.5 million in company shares - Investing.com India
BeiGene's president sells $12.5 million in company shares - Investing.com
Beigene's Wang Xiaodong sells $9.4 million in shares - Investing.com India
Beigene's Wang Xiaodong sells $9.4 million in shares By Investing.com - Investing.com South Africa
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
CCBI Adds BEIGENE's TP to $179 for Better Fundamentals This Yr - AASTOCKS.com
BEIGENE (06160.HK) Climbs 6% in Early Session, Expects to Achieve Positive Operating Income This Yr - AASTOCKS.com
Beigene Ltd Adr (ONC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Beigene Ltd Adr 주식 (ONC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Wang Xiaodong | Chair, Scientific Advisory Brd |
Mar 18 '25 |
Sale |
261.28 |
41,760 |
10,911,252 |
0 |
| OYLER JOHN | Chief Executive Officer |
Mar 10 '25 |
Option Exercise |
0.96 |
539,032 |
516,776 |
6,098,625 |
| OYLER JOHN | Chief Executive Officer |
Mar 10 '25 |
Sale |
242.67 |
41,210 |
10,000,483 |
0 |
5.51%
1.15%
자본화:
|
볼륨(24시간):